JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff

When Bristol Myers Squibb unveiled its massive Celgene buyout ahead of 2019's J.P. Morgan Healthcare Conference, executives knew Celgene's blockbuster blood cancer drug Revlimid would face generics sometime in the years that followed. In 2022, the key patent cliff is here.

Fear not, BMS CEO Giovanni Caforio assured investors on Monday. Opening the conference's 2022 edition, Caforio said the combined drugmaker has a plan to grow despite Revlimid generics, which are set to launch in Europe, Japan and the U.S. this year.